Cited by 518Lung Cancer Treatments and MutationsBrain Metastases and TreatmentLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

Wu, Yi-Long, Ahn, Myung-Ju, Garassino, Marina Chiara, Han, Ji-Youn, Katakami, Nobuyuki, Kim, Hye Ryun, Hodge, Rachel, Kaur, Paramjit, Brown, Andrew P., Ghiorghiu, Dana, Papadimitrakopoulou, Vassiliki A., Mok, Tony S.K.·2018·Journal of Clinical Oncology

DOI 10.1200/jco.2018.77.9363

Open this paper in CoChat — free account

Abstract

Purpose In patients with epidermal growth factor receptor ( EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC), there is an unmet need for EGFR-tyrosine kinase inhibitors with improved CNS penetration and activity against CNS metastases, either at initial diagnosis or time of progression. We report the first comparative evidence of osimertinib CNS efficacy versus platinum-pemetrexed from a phase III study (AURA3; ClinicalTrials.gov identifier: NCT02151981) in patients with EGFR T790M-positive advanced NSCLC who experience disease progression with prior EGFR-tyrosine kinase inhibitor treatment. Methods Patients with asymptomatic, stable CNS metastases were eligible for enrollment and were randomly assigned 2:1 to osimertinib 80 mg once daily or platinum-pemetrexed. A preplanned subgroup analysis was conducted in patients with measurable and/or nonmeasurable CNS lesions on baseline brain scan by blinded independent central neuroradiological review. The CNS evaluable for response set included only patients with one or more measurable CNS lesions. The primary objective for this analysis was CNS objective response rate (ORR). Results Of 419 patients randomly assigned to treatment, 116 had measurable and/or nonmeasurable CNS lesions, including 46 patients with measurable CNS lesions. At data cutoff (April 15, 2016), CNS ORR in patients with one or more measurable CNS lesions was 70% (21 of 30; 95% CI, 51% to 85%) with osimertinib and 31% (5 of 16; 95% CI, 11% to 59%) with platinum-pemetrexed (odds ratio, 5.13; 95% CI, 1.44 to 20.64; P = .015); the ORR was 40% (30 of 75; 95% CI, 29% to 52%) and 17% (7 of 41; 95% CI, 7% to 32%), respectively, in patients with measurable and/or nonmeasurable CNS lesions (odds ratio, 3.24; 95% CI, 1.33 to 8.81; P = .014). Median CNS duration of response in patients with measurable and/or nonmeasurable CNS lesions was 8.9 months (95% CI, 4.3 months to not calculable) for osimertinib and 5.7 months (95% CI, 4.4 to 5.7 months) for platinum-pemetrexed; median CNS progression-free survival was 11.7 months and 5.6 months, respectively (hazard ratio, 0.32; 95% CI, 0.15 to 0.69; P = .004). Conclusion Osimertinib demonstrated superior CNS efficacy versus platinum-pemetrexed in T790M-positive advanced NSCLC.

Integrity signals

Registry

Crossref · 10.1200/jco.2018.77.9363

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Self-citation
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial
Mulvenna, P., Nankivell, M. G., Barton, R., Finn, C. F., Wilson, P., McColl, E., MOORE, B. J., Brisbane, I., Ardron, D., Holt, T., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30825-x · Cited by 723
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Ballard, P., Yates, J. W. T., Yang, Z., Kim, D.-W., Yang, J. C.-H., Cantarini, M., Pickup, K., Jordan, A., Hickey, M., Grist, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0399 · Cited by 718
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Goss, G. D., Tsai, C., Shepherd, F. A., Bazhenova, L. A., Lee, J. S., Chang, G., Crinò, L., Satouchi, M., Chu, Q. S.-C., Hida, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30508-3 · Cited by 654
Self-citation
Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component
Yang, J. C.-H., Ahn, M.-J., Kim, D.-W., Ramalingam, S. S., Sequist, L. V., Su, W.-C., Kim, S.-W., Kim, J.-H., Planchard, D., Felip, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3223 · Cited by 571
Self-citation
Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
Rangachari, D., Yamaguchi, N., VanderLaan, P. A., Folch, E. E., Mahadevan, A., Floyd, S., Uhlmann, E. J., Wong, E. T., Dahlberg, S. E., Huberman, M. S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.020 · Cited by 547
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
Togashi, Y., Masago, K., Masuda, S., Mizuno, T., Fukudo, M., Ikemi, Y., Sakamori, Y., Nagai, H., Kim, Y. H., Katsura, T., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1929-4 · Cited by 282
Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease
Hoffknecht, P., Tufman, A., Wehler, T., Pelzer, T., Wiewrodt, R. G., Schütz, M., Serke, M. H., Stöhlmacher-Williams, J., Märten, A., Huber, R. M., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000380 · Cited by 259
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials
Goss, G., Tsai, C.-M., Shepherd, F. A., Ahn, M.-J., Bazhenova, L., Crinò, L., de Marinis, F., Felip, E., Morabito, A., Hodge, R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx820 · Cited by 247
Self-citation

Flagged first, then by citations

Show all 18 references

Sorted by citations

Items 201–300 of 518

The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in the Therapy of Advanced NSCLC
Wang, F., & Zhou, Q. H. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.01.007 · Cited by 16
Discovery of novel EGFR-PROTACs capable of degradation of multiple EGFR-mutated proteins
Du, Y., Shi, S., Chen, S., He, Y., Xu, W., Wu, D., Tian, Y., Kong, M., He, J., Xie, W., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116489 · Cited by 16
Single- versus 2-session Gamma Knife surgery for symptomatic midsize brain metastases: a propensity score–matched analysis
Yomo, S., Oda, K., & Oguchi, K. (2020) · Journal of neurosurgery · doi:10.3171/2019.7.jns191193 · Cited by 16
Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era
Carlo, E. D., Bertoli, E., Conte, A. D., Stanzione, B., Berto, E., Revelant, A., Spina, M., & Bearz, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126477 · Cited by 15
Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation–Positive, MET-Amplified Non–Small Cell Lung Cancer Model
Jones, R. D. O., Petersson, K., Tabatabai, A., Bao, L., Tomkinson, H. K., & Schuller, A. G. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0193 · Cited by 15
Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis
Azad, T. D., Nanjo, S., Jin, M. C., Chabon, J. J., Kurtz, D. M., Chaudhuri, A. A., Connolly, I. D., Hui, A. B., Liu, C. L., Merriott, D. J., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00582-1 · Cited by 15
Self-citation
Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status
Zhang, M., Ma, W., Liu, H., Jiang, Y., Qin, L., Li, W., & Zhang, J. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/6968194 · Cited by 15
Retracted
Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer
Verhoek, A., Cheema, P. K., Melosky, B. L., Samson, B., Shepherd, F. A., de Marinis, F., John, T., Wu, Y.-L. L. C., Heeg, B. M. S., Dalfsen, N. V., et al. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-023-00396-0 · Cited by 15
Self-citation
Treatment modes for EGFR mutations in patients with brain metastases from non-small cell lung cancer: controversy, causes, and solutions
Zhuang, H., Shi, S., & Chang, J. Y. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.07.03 · Cited by 15
Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer
Lee, V. H.-F., Mok, T. S. K., Goto, Y., Hsue, V. C. C., Li, Y., Jiang, Y., Leung, D. K. C., Lau, K. S., & Tse, P. Y. H. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.07.014 · Cited by 14
Self-citation
Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation
Hu, X., Chen, W., Li, X., Zhao, C., Zhang, C., Xiong, F., & Wu, H. (2019) · Annals of Palliative Medicine · doi:10.21037/apm.2019.10.13 · Cited by 14
A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment
Vishwanathan, K., Sanchez-Simon, I., Keam, B., Penel, N., Miguel, M. J. D., Weilert, D. K., Mills, A., Marotti, M., Johnson, M. G., & Ravaud, A. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.613 · Cited by 14
Real-World Data on Treatment Outcomes in EGFR -Mutant Non-Small-Cell Lung Cancer Patients Receiving Osimertinib in Second or Further Lines
Maso, A. D., Lorenzi, M., Ferro, A., Pilotto, S., Cecere, F. L., Follador, A., Polo, V., Conte, A. D., Sartori, G., Giavarra, M., et al. (2021) · Future Oncology · doi:10.2217/fon-2021-0356 · Cited by 14
Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis
Yang, F., Zhang, W., Shang, X., Liu, G., Ma, X., Qin, J., Zhang, Y., Liu, Y., & Wang, X. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103760 · Cited by 14
Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
Ye, Q., Xu, Y., Zhao, J., Gao, X., Chen, M., Pan, R., Zhong, W., & Wang, M. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101637 · Cited by 14
Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases
Ponce, S., Bruna, J., Juan, Ó., Castro, R. L., Navarro, A., Granados, A. L. O., Puente, J., Verger, E., Bartolomé, A. G., & Nadal, E. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.03.017 · Cited by 14
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD
Riess, J. W., Yu, H. A., Le, X., de Langen, A. J., Cho, B. C., Piotrowska, Z., Hendriks, L. E. L., Morabito, A., Bonanno, L., Brustugun, O. T., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.02.014 · Cited by 14
Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non‐small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study
Ekman, S., Cselényi, Z., Varrone, A., Jučaitė, A., Martin, H., Schou, M., Johnström, P., Laus, G., Lewensohn, R., Brown, A. P., et al. (2023) · Clinical and Translational Science · doi:10.1111/cts.13500 · Cited by 13
Self-citation
Brain metastasis: An insight into novel molecular targets for theranostic approaches
Santos, L., Moreira, J. N., Abrunhosa, A., & Gomes, C. M. F. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104377 · Cited by 13
Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients
Reale, M. L., Chiari, R., Tiseo, M., Vitiello, F., Barbieri, F., Cortinovis, D. L., Ceresoli, G. L., Finocchiaro, G., Romano, G. D., Piovano, P. L., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.12.006 · Cited by 13
Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
Liu, K., Jiang, G., Zhang, A., Li, Z., & Jia, J. (2020) · BMC Cancer · doi:10.1186/s12885-020-6543-y · Cited by 13
Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status
Xu, H., Chen, H., Kong, J.-X., Zhang, Y., Liu, S., Yang, G., Yang, L., & Wang, Y. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-1249 · Cited by 13
Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis
Yang, X., Zeng, Y., Tan, Q., Huang, Z., Jia, J., & Jiang, G. (2022) · Journal of Immunology Research · doi:10.1155/2022/4518898 · Cited by 13
Neurologic complications of lung cancer
Sands, J. M., Daly, M. E., & Lee, E. Q. (2020) · Cancer · doi:10.1002/cncr.32772 · Cited by 13
Brain metastases in EGFR-positive non-small cell lung cancer: the way to the sanctuary becomes less winding
Passaro, A., Gianoncelli, L., Stati, V., & de Marinis, F. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.04.04 · Cited by 13
Osimertinib in EGFR -Mutated Advanced NSCLC
Revannasiddaiah, S., Devadas, S. K., & Maka, V. V. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2001514 · Cited by 13
Lurasidone Sensitizes Cancer Cells to Osimertinib by Inducing Autophagy and Reduction of Survivin
Suzuki, S., Yamamoto, M., Sanomachi, T., Togashi, K., Seino, S., Sugai, A., Yoshioka, T., Okada, M., & Kitanaka, C. (2021) · Anticancer Research · doi:10.21873/anticanres.15237 · Cited by 12
European and US Real-World Treatment Patterns in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Medical Record Review
Shah, R. N. H., Girard, N., Nagar, S. P., Griesinger, F., Roeper, J., Davis, K. L., Karimi, P., Sawyer, W., Yu, N., Taylor, A., et al. (2021) · Drugs - Real World Outcomes · doi:10.1007/s40801-021-00261-8 · Cited by 12
Stereotactic radiotherapy vs whole brain radiation therapy in EGFR mutated NSCLC: Results & reflections from the prematurely closed phase III HYBRID trial
Zeng, M., Verma, V., Chen, X., Li, S., Sun, Y., Liu, G., Tian, X., Zhang, D., Li, J., Liu, Y., et al. (2024) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2024.110334 · Cited by 12
Comparative Efficacy of Systemic Agents for Brain Metastases From Non-Small-Cell Lung Cancer With an EGFR Mutation/ALK Rearrangement: A Systematic Review and Network Meta-Analysis
Taslimi, S., Brar, K., Ellenbogen, Y., Deng, J., Hou, W., de Moraes, F. Y., Glantz, M., Zacharia, B. E., Tan, A. C., Ahluwalia, M. S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.739765 · Cited by 12
Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysis
Bian, D. J. H., Lazaratos, A.-M., Maritan, S. M., Quaiattini, A., Zeng, Z., Zhu, Z., Sener, U. T., Malani, R., Kim, Y. J., Ichihara, E., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29668 · Cited by 12
Cross-sectional survey of patients, caregivers, and physicians on diagnosis and treatment of brain metastases
Kim, A. E., Wang, G.-M., Waite, K. A., Elder, S., Fine, A., Ahluwalia, M. S., Brat, D. J., Mehta, M. P., Page, R., Dunbar, E. M., et al. (2021) · Neuro-Oncology Practice · doi:10.1093/nop/npab042 · Cited by 12
Individualized Nomogram for Predicting Survival in Patients with Brain Metastases After Stereotactic Radiosurgery Utilizing Driver Gene Mutations and Volumetric Surrogates
Zhou, C., Shan, C., Lai, M., Zhou, Z., Zhen, J., Deng, G., Li, H., Li, J., Ren, C., Wang, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.659538 · Cited by 12
First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments
Nie, N., Li, J., Zhang, J., Dai, J., Liu, Z., Ding, Z., Wang, Y., Zhu, M., Hu, C., Han, R., et al. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549221134735 · Cited by 12
CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
Kang, L., Mai, J., Liang, W., Zou, Q., Huang, C., Lin, Y., & Liang, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1094195 · Cited by 11
3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib
Meraz, I. M., Majidi, M., Fang, B., Meng, F., Gao, L., Shao, R., Song, R., Li, F., Lissanu, Y., Chen, H., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04889-w · Cited by 11
Inorganic sulfides prevent osimertinib-induced mitochondrial dysfunction in human iPS cell-derived cardiomyocytes
Kondo, M., Nakamura, Y., Kato, Y., Nishimura, A., Fukata, M., Moriyama, S., Ito, T., Umezawa, K., Urano, Y., Akaike, T., et al. (2024) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2024.07.007 · Cited by 12
Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study
Han, J., Ahn, M., Lee, K. H., Lee, Y., Kim, D., Min, Y. J., Kim, S., Cho, E. K., Kim, J.-H., Lee, G., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03620-8 · Cited by 11
Self-citation
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib
Riess, J. W., Langen, A. J. D., Ponce, S., Goldberg, S. B., Piotrowska, Z., Goldman, J. W., Le, X., Cho, B. C., Yoneshima, Y., Ambrose, H., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00818 · Cited by 12
High-Dose Aumolertinib for Untreated EGFR -Variant Non–Small Cell Lung Cancer With Brain Metastases
Li, H., Chen, K., Gong, L., Qin, J., Jin, Y., Zhou, R., Huang, Z., Xu, Y., Xu, X., He, J., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.1779 · Cited by 12
Betacellulin drives therapy resistance in glioblastoma
Fan, Q.-W., An, Z., Wong, R. A., Luo, X., Lu, E. D., Baldwin, A. S., Mayekar, M. K., Haderk, F., Shokat, K. M., Bivona, T. G., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz206 · Cited by 11
Overcoming the acquired resistance to gefitinib in lung cancer brain metastasis in vitro and in vivo
Liu, Z., Shah, N., Marshall, K. L., Sprowls, S. A., Saralkar, P. A., Mohammad, A. S., Blethen, K. E., Arsiwala, T. A., Fladeland, R. A., Lockman, P. R., et al. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03147-4 · Cited by 11
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data
Cheema, P. K., Cho, B. C., Freitas, H., Provencio, M., Chen, Y.-M., Kim, S., Wu, Y.-L. L. C., Passaro, A., Martin, C. M., Tiseo, M., et al. (2023) · Future Oncology · doi:10.2217/fon-2022-0919 · Cited by 11
Self-citation
Advances in the Management of Central Nervous System Metastases in Non-Small Cell Lung Cancer
D’Aiello, A., Miao, E., & Cheng, H. (2023) · Cancers · doi:10.3390/cancers15030844 · Cited by 13
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study
van der Wel, T. J. W. T., Boelens, M. C., Jebbink, M., Smulders, S. A., Maas, K. W., Luitse, M. J. A., Compter, A., Boltjes, R. P. B., Sol, N., Monkhorst, K., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae138 · Cited by 11
Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer
Stratmann, J., Michels, S. Y. F., Hornetz, S., Christoph, D. C., Sackmann, S., Spengler, W., Bischoff, H. G., Schäfer, M., Alt, J. A., Müller, A. M., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2754-x · Cited by 11
Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice
Higuchi, T., Oshiro, H., Zhang, Z., Miyake, K., Sugisawa, N., Katsuya, Y., Yamamoto, N., Hayashi, K., Kimura, H. J., Miwa, S., et al. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.01.007 · Cited by 11
Biomarker Testing Rates in Patients with Advanced Non-Small Cell Lung Cancer Treated in the Community
Nadler, E., Pavilack, M., Clark, J., Espirito, J. L., & Fernandes, A. W. (2019) · Journal of Cancer Therapy · doi:10.4236/jct.2019.1012083 · Cited by 11
Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study
Peng, D., Shan, D., Dai, C., Li, J., Wang, Z., Huang, Z., Peng, R., Zhao, P., & Ma, X. (2021) · Cancer Management and Research · doi:10.2147/cmar.s287466 · Cited by 11
Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells
Fujiwara, R., Taniguchi, Y., Rai, S., Iwata, Y., Fujii, A., Fujimoto, K., Kumode, T., Serizawa, K., Morita, Y., Espinoza, J. L., et al. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.08.010 · Cited by 13
Liquid biopsy for the management of NSCLC patients under osimertinib treatment
Ntzifa, A., Marras, T., Georgoulias, V., & Lianidou, E. S. (2024) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2024.2302116 · Cited by 10
Population Pharmacokinetics of Osimertinib in Patients With Non‐Small Cell Lung Cancer
Johnson, M. G., Lin, Y., Schmidt, H., Sunnåker, M., van Maanen, E., Huang, X., Rukazenkov, Y., Tomkinson, H. K., & Vishwanathan, K. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70098 · Cited by 10
Standard-Dose Osimertinib in EGFR-Mutated Non–Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease
McLean, L. S., Faisal, W., Parakh, S., Kao, S. C.-H., Lewis, C. R., Chin, M. T. M., Voskoboynik, M., Itchins, M., Jennens, R. R., Broad, A., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00464 · Cited by 10
Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis
Yi, X.-F., Song, J., Gao, R.-L., Sun, L., Wu, Z., Zhang, S., Huang, L., Ma, J., & Han, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.863666 · Cited by 10
Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT)
Janžič, U., Turnšek, N., Dediu, M., Donev, I. S., Lupu, R., Teodorescu, G., Ciuleanu, T., & Płużański, A. (2022) · Current Oncology · doi:10.3390/curroncol29080460 · Cited by 10
FACILITATE: A real-world, multicenter, prospective study investigating the utility of a rapid, fully automated real-time PCR assay versus local reference methods for detecting epidermal growth factor receptor variants in NSCLC
Behnke, A., Cayre, A., Maglio, G. D., Giannini, G., Habran, L., Tarsitano, M., Chetta, M., Cappellen, D., Lespagnol, A., Naourès, C. L., et al. (2023) · Pathology & Oncology Research · doi:10.3389/pore.2023.1610707 · Cited by 10
Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib
Kian, W., Krayim, B., Alsana, H., Giles, B., Purim, O., Alguayn, W., Alguayn, F., Peled, N., & Roisman, L. C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1124949 · Cited by 10
Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer
Li, Y.-S., Jie, G., & Wu, Y.-L. L. C. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231193726 · Cited by 10
Self-citation
EGFR inhibitor erlotinib plus monoclonal antibody versus erlotinib alone for first-line treatment of advanced non-small cell lung carcinoma: A systematic review and meta-analysis
Liu, M., Xiao, K., & Yang, L. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110001 · Cited by 10
Real-world use of osimertinib in non–small cell lung cancer: ASTRIS study Korean subgroup analysis
Cho, B. C., Kim, D., Park, K., Lee, J.-S., Yoo, S. S., Kang, J. H., Lee, S. Y., Kim, C. H., Jang, S. H., Kim, Y., et al. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1676708 · Cited by 10
Self-citation
Targeting EGFR in glioblastoma with a novel brain-penetrant small molecule EGFR-TKIPreprint
Ni, J., Yang, Y., Wang, Q., Bergholz, J. S., Jiang, T., Roberts, T. M., Gray, N. S., & Zhao, J. J. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.09.426030 · Cited by 10
Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Maroni, G., Krishnan, I., Alfieri, R. R., Maymi, V. A., Pandell, N., Csizmadia, E., Zhang, J., Weetall, M. L., Branstrom, A., Braccini, G., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0161 · Cited by 9
Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer
Hori, T., Yamamoto, K., Ito, T., Ikushima, S., Omura, T., & Yano, I. (2024) · Investigational New Drugs · doi:10.1007/s10637-024-01432-4 · Cited by 9
Exposure–response modelling of osimertinib in patients with non‐small cell lung cancer
Johnson, M. G., Lin, Y., Schmidt, H., Sunnåker, M., van Maanen, E., Huang, X., Rukazenkov, Y., Tomkinson, H. K., & Vishwanathan, K. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16199 · Cited by 9
Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer
Waliany, S., Lin, J. J., & Gainor, J. F. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.01.005 · Cited by 10
Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study
Eide, I. J. Z., Grut, H., Helland, Å., Ekman, S., Sørensen, J. B., Hansen, K. H., Grønberg, B. H., Cicenas, S., Koivunen, J. P., Mellemgaard, A., et al. (2021) · Acta Oncologica · doi:10.1080/0284186x.2021.1973092 · Cited by 9
Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC
Novak, J., Salgia, R., West, H., Villalona-Calero, M. A., Sampath, S., Williams, T. M., Villaflor, V. M., Massarelli, E., Pathak, R., Koczywas, M., et al. (2022) · Cancers · doi:10.3390/cancers14163983 · Cited by 9
Clinicopathologic outcomes of preoperative targeted therapy in patients with clinical stage I to III non–small cell lung cancer
Lengel, H. B., Zheng, J., Tan, K. S., Liu, C. C., Park, B. J., Rocco, G., Adusumilli, P. S., Molena, D., Yu, H. A., Riely, G. J., et al. (2022) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2022.10.056 · Cited by 9
Rationale and value of consolidative cranial local therapy in EGFR-mutant non-small cell lung cancer patients with baseline brain metastasis treated with first-line EGFR-TKIs
Zeng, Y., Su, X., Zhao, Y., Zhou, Y., Guo, T., Chu, X., Chu, L., Yang, X., Ni, J., & Zhu, Z. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231169975 · Cited by 9
Molecular Profiling and Targeted Therapies in Gliomas
Felistia, Y., & Wen, P. Y. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01299-7 · Cited by 9
Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First‐Line Mutant Epidermal Growth Factor Receptor Non‐Small Cell Lung Cancer
Johnson, M. G., Traynor, C. S., Vishwanathan, K., Overend, P., Hartmaier, R. J., Markovets, A. A., Chmielecki, J., Mugundu, G. M., Barrett, J. C., Tomkinson, H. K., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3113 · Cited by 9
Advances in the Management of Lung Cancer Brain Metastases
Hockemeyer, K., Rusthoven, C. G., & Pike, L. (2024) · Cancers · doi:10.3390/cancers16223780 · Cited by 10
Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma
Li, C., Guo, J., Zhao, L., Hu, F., Nie, W., Wang, H., Zheng, X., Shen, Y., Gu, P., Zhang, Y., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s196881 · Cited by 9
Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT)
Addeo, A., Hochmair, M. J., Janžič, U., Dudnik, E., Charpidou, A. G., Płużański, A., Ciuleanu, T., Donev, I. S., Elbaz, J., Aarøe, J., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211059874 · Cited by 9
Dynamics of eligibility criteria for central nervous system metastases in non-small cell lung cancer randomized clinical trials over time: A systematic review
Schoenmaekers, J. J. A. O., Dursun, S., Biesmans, C., Ruysscher, D. D., Broen, M. P. G., Remón, J., Dingemans, A. C., & Hendriks, L. E. L. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103460 · Cited by 9
Executive summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small cell lung cancer
Nagpal, S., Milano, M. T., Chiang, V., Soltys, S. G., Brackett, A. L., Halasz, L. M., Garg, A. K., Sahgal, A., Ahluwalia, M. S., Tom, M. C., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae041 · Cited by 9
Resistance mutations and the blood–brain barrier: Key challenges in targeted treatment of brain metastatic non-small cell lung cancer
Rijmers, J., Lebre, M. C., Beijnen, J. H., & Schinkel, A. H. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.06.002 · Cited by 9
TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with EGFR -mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib
Tan, D. S., Nadal, E., Cheema, P. K., Wu, Y., Ahn, M., Tanizaki, J., Grainger, E., Nizialek, E. A., Forcina, A., van der Gronde, T., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251385410 · Cited by 8
Self-citation
An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update
Cerbone, L., Benítez, J. C., Planchard, D., & Genova, C. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1888928 · Cited by 8
Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer
Liu, X., Li, G., Zhang, H., Chang, Q., Fang, M., Lu, C., Tian, P., & Mei, F.-J. (2022) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2022.107572 · Cited by 8
Double-dose osimertinib combined with intrathecal injection of pemetrexed improves the efficacy of EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis: case report and literature review
Zhong, W., Wu, L., Huang, L., Wang, J., Shi, H., & Wu, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1377451 · Cited by 9
Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer
Poh, M. E., Balakrishnan, S., Tan, S. N., Abidin, M. A. Z., Liam, C. K., Tan, J. L., Pang, Y. K., Alaga, A., Tho, L. M., & How, S. H. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-243 · Cited by 8
Treatment Patterns and Clinical Outcomes in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer After Progression on Osimertinib
Robinson, N. D., Canavan, M., Zhan, P. L., Udelsman, B. V., Pathak, R., Boffa, D. J., & Goldberg, S. B. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.09.006 · Cited by 8
Targeting exon mutations in NSCLC: clinical insights into LAG-3, TIM-3 pathways, and advances in fourth-generation EGFR-TKIs
Kannan, K., & Mohan, S. (2025) · Medical Oncology · doi:10.1007/s12032-025-02755-9 · Cited by 8
Treatment Patterns in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: Analysis of US Insurance Claims Databases
Soo, R. A., Seto, T., Gray, J. E., Thiel, E., Taylor, A., Sawyer, W., Karimi, P., Marchlewicz, E. H., & Brouillette, M. A. (2021) · Drugs - Real World Outcomes · doi:10.1007/s40801-021-00272-5 · Cited by 8
Kinase Inhibitors Involved in the Regulation of Autophagy: Molecular Concepts and Clinical Implications
Al‐Huseini, I., Sirasanagandla, S. R., Babu, K. S., Sofin, R. G. S., & Das, S. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220117114306 · Cited by 8
Upfront Advanced Radiotherapy and New Drugs for NSCLC Patients with Synchronous Brain Metastases: Is the Juice Worth the Squeeze? A Real-World Analysis from Lombardy, Italy
Corrao, G., Franchi, M., Zaffaroni, M., Vincini, M. G., de Marinis, F., Spaggiari, L., Orecchia, R., Marvaso, G., & Jereczek‐Fossa, B. A. (2023) · Cancers · doi:10.3390/cancers15041103 · Cited by 8
Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer
Hines, J. B., Bowar, B., Levine, E. E., Esposito, A., Garassino, M. C., & Bestvina, C. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119429 · Cited by 8
Self-citation
Recommended first-line management of asymptomatic brain metastases from EGFR mutant and ALK positive non-small cell lung cancer varies significantly according to specialty: an international survey of clinical practice
Fong, C. H., Meti, N., Kruser, T. J., Weiss, J., Liu, Z. A., Takami, H., Narita, Y., de Moraes, F. Y., Dasgupta, A., Ong, C. K., et al. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-22-697 · Cited by 8
Therapeutic options for advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer: a Bayesian network secondary analysis
Xinmin, Z., Wan, X., Xu, J. H., Wang, H., Chen, H., Zeng, Q., Zhang, W., & Zhao, B. (2020) · Aging · doi:10.18632/aging.103066 · Cited by 8
A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L)
Wakuda, K., Yamaguchi, H., Kenmotsu, H., Fukuda, M., Takeshita, M., Suetsugu, T., Kirita, K., Ebi, N., Hataji, O., Miura, S., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06874-6 · Cited by 8
Comparison of partitioned survival modeling with state transition modeling approaches with or without consideration of brain metastasis: a case study of Osimertinib versus pemetrexed-platinum
Shim, Y. M., Oh, B.-C., Lee, E., & Park, M.-H. (2024) · BMC Cancer · doi:10.1186/s12885-024-11971-x · Cited by 7
Class I HLA Alleles Are Associated With an Increased Risk of Osimertinib-Induced Hypersensitivity
Chen, C., Wang, C., Lu, C., Chen, W., Zhou, B., Chu, C., Hsu, S.-F., Yang, C., Chang, J. W., Yang, C., et al. (2024) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2024.10.027 · Cited by 7
Osimertinib for EGFR ‐Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First‐Generation EGFR ‐ TKI Resistance
Zhang, Y., Xu, Y., Xu, J., Zhong, H., Xia, J., & Zhong, R. (2024) · Cancer Science · doi:10.1111/cas.16437 · Cited by 7
Perioperative Strategies in Resectable Non-Squamous Non-Small Cell Lung Cancer with EGFR Mutations and ALK Rearrangement
Petrella, F., Cara, A., Cassina, E. M., Degiovanni, S., Libretti, L., Torto, S. L., Pirondini, E., Raveglia, F., Spinelli, F., Tuoro, A., et al. (2025) · Cancers · doi:10.3390/cancers17111844 · Cited by 7
Difference in central nerve system metastasis during gefitinib or erlotinib therapy in patients with EGFR-mutated non-small cell lung cancer: a retrospective study
Yoshida, K., Kanda, S., Shiraishi, H., Goto, K., Itahashi, K., Goto, Y., Horinouchi, H., Fujiwara, Y., Nokihara, H., Yamamoto, N., et al. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.03.61 · Cited by 7
Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US
Kong, A. M., Pavilack, M., Huo, H., Shenolikar, R. A., Moynihan, M., Marchlewicz, E. H., Chebili-Larson, C., Min, S., & Subramaniam, D. S. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.1885418 · Cited by 7
Safety and Efficacy of Osimertinib in Patients With Non–Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis
Priantti, J. N., Fujiwara, Y., de Moraes, F. C. A., Michelon, I. F., Castro, C., Leighl, N. B., Cavalcante, L. L., Addeo, A., Bar, J., Horita, N., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00331 · Cited by 7
Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment
Yang, Y., Liu, Q., Cao, L., Sun, W., Gu, X., Liu, B., Xiao, N., Teng, F., Li, X., Chen, M.-J., et al. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01539-x · Cited by 7
Resistance Profile of Osimertinib in Pre-treated Patients With EGFR T790M-Mutated Non-small Cell Lung Cancer
Fernandes, M. G. O., Sousa, C., Jacob, M., Almeida, L. M., Santos, V., Araújo, D., Bastos, H. N., Magalhães, A., Cirnes, L., Moura, C. S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.602924 · Cited by 7

Authors: Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Han, J.-Y., Katakami, N., Kim, H. R., Hodge, R., Kaur, P., Brown, A. P., Ghiorghiu, D., Papadimitrakopoulou, V. A., & Mok, T. S. K.
Affiliations: Yonsei University (KR)
ORCID: Wu, Yi-Long
Ahn, Myung-Ju
Garassino, Marina Chiara
Han, Ji-Youn
Katakami, Nobuyuki
Kim, Hye Ryun
Hodge, Rachel
Papadimitrakopoulou, Vassiliki A.
Mok, Tony S.K.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2018-09-10
Volume: 36
Issue: 26
Pages: 2702-2709
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2018.77.9363
OpenAlex: W2887416920
Cited by: 517
References: 18
Citations by year: 2026: 30 · 2025: 59 · 2024: 63 · 2023: 79 · 2022: 66 · 2021: 75 · 2020: 70 · 2019: 62 · 2018: 13
FWCI: 41.63
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Brain Metastases and Treatment
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: osimertinib, T790M mutation, advanced non-small cell lung cancer, central nervous system metastasis, EGFR tyrosine kinase inhibitors, CNS penetration, AURA3 trial, subgroup analysis
MeSH terms: Pemetrexed, Acrylamides, Adult, Aged, Aged, 80 and over, Aniline Compounds, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Mutation, Pyrimidines, Carboplatin, Protein Kinase Inhibitors, Young Adult, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks